If you are able to find a laboratory that provides a test you require that is not covered by the test directory, please refer to their website for details of how to transport the sample and for a referral form.
CYP2C19 genotyping to guide mavacamten dosing
The referral form below should be completed for referrals for CYP2C19 genotyping to guide mavacamten dosing.
Please send the completed referral form and the labelled patient sample (3-5ml of EDTA blood) to the NWGLH – Liverpool site at the following address:
North West Genomic Laboratory Hub – Liverpool Site
Manchester Centre for Genomic Medicine
Sample Reception (2nd Floor)
Liverpool Women’s Hospital
Note: If ordering a CYP2C19 test for a patient that has been prescribed CAMZYOS (mavacamten) for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients, please note this test will only be funded by Bristol Myers Squibb under a package deal if a written agreement is in place between Bristol Myers Squibb and your Trust. If no agreement is in place, the test cannot be funded by Bristol Myers Squibb. For questions relating to the package deal please contact your local Bristol Myers Squibb representative. Please note, CYP2C19 testing can be ordered outside of the package deal but will not be reimbursed by Bristol Myers Squibb and will be invoiced separately.